Cause and management of therapy resistance.
| Related Articles |
Cause and management of therapy resistance.
Best Pract Res Clin Haematol. 2009 Sep;22(3):367-79
Authors: Hochhaus A, Schenk T, Erben P, Ernst T, La Rosée P, Müller MC
A minority of patients treated with imatinib are either refractory to imatinib or eventually relapse. Relapse frequently depends on re-emergence of BCR-ABL kinase activity but may also indicate BCR-ABL-independent disease progression. Over 90 point mutations coding for single amino acid substitutions in the BCR-ABL kinase domain have been isolated from CML patients resistant to imatinib treatment. These mutations affect amino acids involved in imatinib binding or in regulatory regions of the BCR-ABL kinase domain, resulting in decreased sensitivity to imatinib while retaining aberrant kinase activity. The early detection of BCR-ABL mutants during therapy may aid in risk stratification as well as molecular-based treatment decisions. Therapeutic strategies of imatinib resistant disease include novel tyrosine kinase inhibitors with activity against imatinib-resistant mutations and/or with inhibition of alternative pathways, dose escalation to optimise imatinib levels, treatment interruption to stop selection of resistant cells and allogeneic stem cell transplantation in eligible patients.
PMID: 19959087 [PubMed - in process]
Sponsored Content:
This entry was posted on Sunday, December 6th, 2009 at 7:48 am and is filed under Best Pract Res Clin Haematol. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.
